Vivek Subbiah, MD, MD Anderson Cancer Center


Dr. Subbiah on the FDA Approval of Dabrafenib/Trametinib in BRAF V600E–Mutated Solid Tumors

July 27th 2022

Vivek Subbiah, MD, discusses the FDA approval of dabrafenib plus trametinib for the treatment of patients with BRAF V600E–mutated unresectable or metastatic solid tumors.

Future Directions in Treatment of Small Cell Lung Cancer

August 26th 2021

Panelists conclude their discussion by commenting on areas of unmet need and sharing personal perspectives on factors that may change clinical practice for SCLC in the future.

Emerging Treatments in SCLC: Impact of Targeted Therapy

August 26th 2021

Key opinion leaders in lung cancer share personal thoughts on the potential for bispecific agents and the overall impact of inhibiting molecular targets.

Emerging Treatments in SCLC: Triplets + Limited-Stage Disease

August 19th 2021

Anne Chiang, MD, PhD, reviews the study design of 2 clinical trials, adding a third agent to the standard-of-care regimen of chemotherapy plus I/O; Stephen Liu, MD, discusses clinical trials in limited-stage disease.

Emerging Treatments in SCLC: Targeting DNA Damage

August 19th 2021

Thoracic oncology expert Vivek Subbiah, MD, provides an overview of recent clinical trials studying agents targeting DNA damage for the treatment of small cell lung cancer.

Emerging Treatments in SCLC: Bispecific Antibodies

August 12th 2021

Expert panelists weigh in on emerging data from recent presentations on small cell lung cancer, including novel immunotherapy approaches such as bispecific antibodies targeting DLL3 or therapies targeting TIGIT.

SCLC: Rechallenging With Chemotherapy + I/O

August 12th 2021

Anne Chiang, MD, PhD, renowned expert in thoracic oncology, guides a discussion on whether to rechallenge with chemotherapy + I/O after progression of small cell lung cancer.

SCLC: Second-Line Options and Supportive Care

August 5th 2021

Key opinion leaders in thoracic oncology provide insights into second-line treatment for patients with relapsed/refractory small cell lung cancer and comment on the role of trilaciclib in managing cisplatin-associated neutropenia.

Single Agent I/O Therapy for Relapsed/Refractory

August 5th 2021

Lung cancer expert Anne Chiang, MD, PhD, considers the recent withdrawal of FDA-accelerated approval for nivolumab and pembrolizumab for patients with relapsed extensive-stage small cell lung cancer.

Treatment After Progression of SCLC: Lurbinectedin

July 29th 2021

Vivek Subbiah, MD, reviews the safety and efficacy of treatment with lurbinectedin in patients who have platinum-sensitive relapsed small cell lung cancer.

Future Directions in ES SCLC

July 29th 2021

Panelists reflect on treatment considerations for asymptomatic brain metastases, progress in biomarker research, and frequency of administering checkpoint inhibitors.

Treatment Considerations: Chemotherapy + IO in ES SCLC

July 22nd 2021

Panelists reflect on key points from recent studies in ES SCLC by discussing patients for whom immunotherapy may be appropriate, examining the role of adding CTLA4 inhibition to a PD-L1 inhibitor, and reviewing factors to consider when deciding between cisplatin or carboplatin.

First-Line Therapy in ES SCLS: KEYNOTE-604

July 22nd 2021

Key opinion leader in lung cancer, Vivek Subbiah, MD, examines the phase 3 KEYNOTE-604 trial of platinum-based chemotherapy + pembrolizumab and considers whether the data support findings from other trials of chemotherapy + IO combination approaches.

First-Line Therapy in ES SCLC: CASPIAN

July 15th 2021

Thoracic oncologist, Anne Chiang, MD, PhD, reviews the trial design and results of the CASPIAN trial and emphasizes implications for long-term benefit of combining platinum chemotherapy with durvalumab.

First-Line Therapy in ES SCLC: IMpower133

July 15th 2021

Stephen Liu, MD guides a discussion on recent updates on IO+chemotherapy combinations in extensive-stage small cell lung cancer by reviewing data from the phase 3 IMpower133 l trial of carboplatin/etoposide/atezolizumab.

Dr. Subbiah on the Clinical Activity of Pralsetinib in RET+ Cholangiocarcinoma

January 16th 2021

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.

Dr. Subbiah on the FDA Approval of Pralsetinib in RET+ NSCLC

September 5th 2020

Vivek Subbiah, MD, discusses the clinical implications of the approval of pralsetinib in patients with RET fusion–positive non–small cell lung cancer.

Q & A and Final Thoughts

August 20th 2020

Unmet Needs and Challenges in Treating R/R SCLC

August 20th 2020

Role of Newer Agents in the Treatment & Patient Selection

August 20th 2020